CLQ is found in 3 entries.

CLQ as free ligands, exist in 3 entries. Examples include 1CET 4FGL 4V2O

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Identifiers (4R)-N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine
Formula C18 H26 Cl N3
Molecular Weight 319.872  g/mol
Isomeric SMILES CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12
InChI InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)/t14-/m1/s1

Chemical Details

Formal Charge 0
Atom Count 48
Chiral Atom Count 1
Chiral Atoms C10
Bond Count 49
Aromatic Bond Count 11
Leaving Atoms n/a

Drug Info: DrugBank

DrugBank ID DB00608   (Different stereochemistry)
Name Chloroquine
Groups approved
Description The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [PubChem]
  • Chloraquine
  • Chlorochin
  • Chlorochine
  • Chloroquina
  • Chloroquine
  • Chloraquine
  • Chlorochin
  • Chlorochine
  • Chloroquina
  • Chloroquine
Brand Names
  • Aralen
  • Chloroquine
  • Chloroquine Phosphate
  • Teva-chloroquine
  • Artrichin
Affected Organism Plasmodium
Indication For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
Pharmacology Chloroquine is the prototype anti malarial drug, most widely used to treat all types of malaria except for disease caused by chloroquine resistant <i>Plasmodium falciparum</i>. It is highly effective against erythrocytic forms of <i>Plasmodium vivax</i>, <i>Plasmodium ovale</i> and <i>Plasmodium malariae</i>, sensitive strains of <i>Plasmodium falciparum</i> and gametocytes of <i>Plasmodium vivax</i>. Being alkaline, the drug reaches high concentration within the food vacuoles of the parasite and raises its pH. It is found to induce rapid clumping of the pigment. Chloroquine inhibits the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. It may also interfere with the biosynthesis of nucleic acids.
Mechanism of action The mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. nside red blood cells, the malarial parasite must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasite cell. During this process, the parasite produces the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a non-toxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals. Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-Chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. In essence, the parasite cell drowns in its own metabolic products.
Route of administration oral
  • Antirheumatic Agents
  • Antimalarials
  • Amebicides
  • Aminoquinolines (Antimalarial)
ATC-Code P01BA01
AHFS-Code 08:30.08
CAS number 54-05-7
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682